Publications by authors named "Daygen Finch"

Claim this Profile
E
ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.
Gillian Vandekerkhove, Andrew J Murtha, David C Müller, Maria Stephenson, Kimia Rostin, Daygen Finch

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
Eric Winquist, Sebastien J Hotte, Kim Chi, Srikala Sridhar, Susan Ellard, Daygen Finch

Clin Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer.
Nicolette M Fonseca, Corinne Maurice-Dror, Cameron Herberts, Wilson Tu, William Fan, Daygen L Finch

Nat Commun· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic testing practices among specialist physicians who treat prostate cancer A Canadian, cross-sectional survey.
Steven M Yip, Christopher Morash, Michael P Kolinsky, Anil Kapoor, Michael Ong, Daygen Finch

Can Urol Assoc J· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BeTTer Outcomes Workgroup Health Quality Initiative to optimize bone health for prostate cancer patients in the British Columbia Cancer System.
Krista Noonan, Jenny J Ko, Peter C Black, Michael Peacock, Daygen Finch

Can Urol Assoc J· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
Matti Annala, Sinja Taavitsainen, Daniel J Khalaf, Gillian Vandekerkhove, Kevin Beja, Daygen L Finch

Clin Cancer Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Maryam Soleimani, Kevin Zou, Katherine Sunderland, Werner Struss, Bernie J Eigl, Daygen Finch

Eur J Cancer· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Daniel J Khalaf, Matti Annala, Sinja Taavitsainen, Daygen L Finch, Conrad Oja

Lancet Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
Daniel J Khalaf, Katherine Sunderland, Bernhard J Eigl, Christian K Kollmannsberger, Nikita Ivanov, Daygen L Finch

Eur Urol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.
Sebastien J Hotte, Kim N Chi, Anthony M Joshua, Donsheng Tu, Robyn J Macfarlane, Daygen Finch

Clin Genitourin Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Jean-Michel Lavoie, Kevin Zou, Daniel Khalaf, Bernhard J Eigl, Christian K Kollmannsberger, Daygen Finch

Prostate· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.
Matti Annala, Gillian Vandekerkhove, Daniel Khalaf, Sinja Taavitsainen, Kevin Beja, Daygen Finch

Cancer Discov· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
Daniel Joseph Khalaf, Claudia M Avilés, Arun A Azad, Katherine Sunderland, Tilman Todenhöfer, Daygen Finch

Can Urol Assoc J· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Ethan Toumishey, Angeli Prasad, Greg Dueck, Neil Chua, Daygen Finch

Cancer· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Greg Dueck, Neil Chua, Angeli Prasad, Daygen Finch, Doug Stewart

Cancer· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy.
Michael M Vickers, Toni K Choueiri, Miranda Rogers, Andrew Percy, Daygen Finch

Urology· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline.
Brendan J W Miles, Adrian S Fairey, Michael Eliasziw, Eric P Estey, Peter Venner, Daygen Finch

Can Urol Assoc J· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment.
Mark Warren, Peter M Venner, Scott North, Tina Cheng, Chris Venner, Daygen Finch

Can Urol Assoc J· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extrapulmonary small cell cancer: a Canadian province's experience.
Kamal Haider, Rabia K Shahid, Daygen Finch, Amer Sami, Imran Ahmad

Cancer· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis